

17 Oct 2018 | News

QUOTED. Oct. 17, 2018. Ian Crosbie.

by

Significant market adoption of Sequana Medica's pump targeting fluid build-up that is linked to liver cirrhosis will depend on the company's ability to reach beyond patients with alcohol-related liver diseases to those with "non-alcoholic steatohepatitis," or NASH, the firm's CEO explains here.

"In Europe, most of our patients have hepatitis or alcohol-related cirrhosis and, even though the hepatologists should be fighting for their treatment, when it comes to hospital administrators, they are still not prioritizing this in their budgets. Our sales will remain limited in Europe until we can break out of our core market and into treating NASH." – Ian Crosbie, CEO, Sequana Medical

- Find out more: [Sequana Medical Pumped About NASH's Market Potential](#)

[Click here](#) for a free trial of *Medtech Insight*